2023 Advances in Cancer Immunotherapyâ„¢: irAEs associated with Cellular Therapies and T-cell Engagers

Published: On 10/05/2023


Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.


Additional support for this activity provided by:


Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.


The course irAES associated with Cellular Therapies and T-cell Engagers starts with an overview of cellular therapies and bisepcific antibodies. Dr. Loretta Nastoupil of UT MD Anderson Cancer Center has described the immune related acute and late adverse events associated with CAR T-cell therapies and potential approches to management of toxicities. The case studies presented by Dr. Nastoupil help decide the best possible action plan for managing toxicities associated with CAR T-cell therapies in patients.

Estimated time to complete activity:  40 Minutes


Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


Learning Objectives
At the conclusion of this activity, the participant should be able to:

  • Give a brief overview of the mechanism of action and common toxicities associated with cellular therapies and T cell engagers.

  • List the multiple approaches that should be followed post treatment.

  • Describe the immune related acute and late adverse events (toxicities) associated with CAR-T cell therapies.

  • Describe similar acute toxicities associated with T-cell engagers and potential different approaches to management.

  • Explain the action plan for the management of toxicities associated with CAR-T cell therapies.


Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.


Faculty and Disclosure of Conflicts of Interest


Loretta Nastoupil, MD
Associate Professor
UT MD Anderson Cancer Center
Texas, USA


The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:


Conflicts of Interest
Researcher: BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
Consultant/ Advisor/ Speaker: Abbvie, Atara, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, Janssen, Merck, Novartis, Takeda

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.


SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

irAEs associated with Cellular Therapies and T-cell Engagers
Individual topic purchase: Selected
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
2023 Advances in Cancer Immunotherapyâ„¢: irAEs associated with Cellular Therapies and T-cell Engagers
SITC Member Price:$0.00
Non-Member Price:$0.00